Iranian Red Crescent Medical Journal

Published by: Kowsar

Daily Consumption of the Capparis spinosa Reduces Some Atherogenic Indices in Patients with Non-alcoholic Fatty Liver Disease: A Randomized, Double-blind, Clinical Trial

Narjes Khavasi 1 , Mohammadhossein Somi 2 , * , Ebrahim Khadem 3 , Mohammad Hossein Ayati 3 , Mohamadali Torbati 4 and Seyyed Muhammad Bagher Fazljou 1
Authors Information
1 Department of Traditional Medicine, Faculty of Traditional Medicine, Tabriz University of Medical Sciences, Tabriz, IR Iran
2 Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, IR Iran
3 Department of Traditional Medicine, School of Traditional Medicine, Tehran University of Medical Sciences, Tehran, IR Iran
4 Department of Food Science and Technology, Faculty of Nutrition, Tabriz University of Medical, Tabriz, IR Iran
Article information
  • Iranian Red Crescent Medical Journal: November 2018, 20 (11); e63446
  • Published Online: May 5, 2018
  • Article Type: Research Article
  • Received: November 9, 2017
  • Revised: December 16, 2017
  • Accepted: February 14, 2018
  • DOI: 10.5812/ircmj.63446

To Cite: Khavasi N, Somi M, Khadem E, Ayati M H, Torbati M, et al. Daily Consumption of the Capparis spinosa Reduces Some Atherogenic Indices in Patients with Non-alcoholic Fatty Liver Disease: A Randomized, Double-blind, Clinical Trial, Iran Red Crescent Med J. 2018 ; 20(11):e63446. doi: 10.5812/ircmj.63446.

Abstract
Copyright © 2018, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods
3. Results
4. Discussion
References
  • 1. Liu H, Lu HY. Nonalcoholic fatty liver disease and cardiovascular disease. World J Gastroenterol. 2014;20(26):8407-15. doi: 10.3748/wjg.v20.i26.8407. [PubMed: 25024598].
  • 2. Hashizume H, Sato K, Yamazaki Y, Horiguchi N, Kakizaki S, Mori M. A prospective study of long-term outcomes in female patients with nonalcoholic steatohepatitis using age- and body mass index-matched cohorts. Acta Med Okayama. 2013;67(1):45-53. doi: 10.18926/AMO/49256. [PubMed: 23439508].
  • 3. Blackett PR, Sanghera DK. Genetic determinants of cardiometabolic risk: a proposed model for phenotype association and interaction. J Clin Lipidol. 2013;7(1):65-81. doi: 10.1016/j.jacl.2012.04.079. [PubMed: 23351585].
  • 4. Huang Y, Bi Y, Xu M, Ma Z, Xu Y, Wang T, et al. Nonalcoholic fatty liver disease is associated with atherosclerosis in middle-aged and elderly Chinese. Arterioscler Thromb Vasc Biol. 2012;32(9):2321-6. doi: 10.1161/ATVBAHA.112.252957. [PubMed: 22814750].
  • 5. Feitosa MF, Reiner AP, Wojczynski MK, Graff M, North KE, Carr JJ, et al. Sex-influenced association of nonalcoholic fatty liver disease with coronary heart disease. Atherosclerosis. 2013;227(2):420-4. doi: 10.1016/j.atherosclerosis.2013.01.013. [PubMed: 23390892].
  • 6. Dogru T, Genc H, Tapan S, Ercin CN, Ors F, Aslan F, et al. Elevated asymmetric dimethylarginine in plasma: an early marker for endothelial dysfunction in non-alcoholic fatty liver disease? Diabetes Res Clin Pract. 2012;96(1):47-52. doi: 10.1016/j.diabres.2011.11.022. [PubMed: 22189171].
  • 7. Alkhouri N, Kistangari G, Campbell C, Lopez R, Zein NN, Feldstein AE. Mean platelet volume as a marker of increased cardiovascular risk in patients with nonalcoholic steatohepatitis. Hepatology. 2012;55(1):331. doi: 10.1002/hep.24721. [PubMed: 21969091].
  • 8. Gawrieh S, Baye TM, Carless M, Wallace J, Komorowski R, Kleiner DE, et al. Hepatic gene networks in morbidly obese patients with nonalcoholic fatty liver disease. Obes Surg. 2010;20(12):1698-709. doi: 10.1007/s11695-010-0171-6. [PubMed: 20473581].
  • 9. Cakir E, Ozbek M, Colak N, Cakal E, Delibasi T. Is NAFLD an independent risk factor for increased IMT in T2DM? Minerva Endocrinol. 2012;37(2):187-93. [PubMed: 22691891].
  • 10. Shidfar F, Jazayeri S, Mousavi SN, Malek M, Hosseini AF, Khoshpey B. Does Supplementation with Royal Jelly Improve Oxidative Stress and Insulin Resistance in Type 2 Diabetic Patients? Iran J Public Health. 2015;44(6):797-803. [PubMed: 26258092].
  • 11. Patel D, Prasad S, Kumar R, Hemalatha S. An overview on antidiabetic medicinal plants having insulin mimetic property. Asia Pacific J Tropic Biomed. 2012;2(4):320-30.
  • 12. Gurney SM, Scott KS, Kacinko SL, Presley BC, Logan BK. Pharmacology, Toxicology, and Adverse Effects of Synthetic Cannabinoid Drugs. Forensic Sci Rev. 2014;26(1):53-78. [PubMed: 26226970].
  • 13. Yang T, Liu YQ, Wang CH, Wang ZT. [Advances on investigation of chemical constituents, pharmacological activities and clinical applications of Capparis spinosa]. Zhongguo Zhong Yao Za Zhi. 2008;33(21):2453-8. [PubMed: 19149246].
  • 14. Tlili N, Mejri H, Anouer F, Saadaoui E, Khaldi A, Nasri N. Phenolic profile and antioxidant activity of Capparis spinosa seeds harvested from different wild habitats. Indust Crop Product. 2015;76:930-5.
  • 15. Kazemian M, Abad M, Haeri MR, Ebrahimi M, Heidari R. Anti-diabetic effect of Capparis spinosa L. root extract in diabetic rats. Avicenna J Phytomed. 2015;5(4):325-32. [PubMed: 26445712].
  • 16. Gull T, Anwar F, Sultana B, Alcayde MAC, Nouman W. Capparis species: A potential source of bioactives and high-value components: A review. Indust Crop Product. 2015;67:81-96.
  • 17. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487-95. [PubMed: 15161807].
  • 18. Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 2014;99(3):535-42. doi: 10.3945/ajcn.113.068890. [PubMed: 24401715].
  • 19. Lorvand Amiri H, Agah S, Mousavi SN, Hosseini AF, Shidfar F. Regression of Non-Alcoholic Fatty Liver by Vitamin D Supplement: A Double-Blind Randomized Controlled Clinical Trial. Arch Iran Med. 2016;19(9):631-8. [PubMed: 27631178].
  • 20. Mousavi SN, Faghihi A, Motaghinejad M, Shiasi M, Imanparast F, Amiri HL. Zinc and Selenium Co-supplementation Reduces Some Lipid Peroxidation and Angiogenesis Markers in a Rat Model of NAFLD-Fed High Fat Diet. Biolog Trac Element Res. 2017:1-8. Persian.
  • 21. Schulz V. Safety of St. John's Wort extract compared to synthetic antidepressants. Phytomedicine. 2006;13(3):199-204. doi: 10.1016/j.phymed.2005.07.005. [PubMed: 16428030].
  • 22. Aveccena. Qanoon fi teb (Fundamentals of Medicines - Diseases - Pharmaceuticals and Industry). Beirut: Dar ol torath ol arabieh; 2005.
  • 23. Emtiazy M, Choopani R, Khodadoost M, Tansaz M, Nazem E. Atheroprotector role of the spleen based on the teaching of Avicenna (Ibn Sina). Int J Cardiol. 2013;167(1):26-8. doi: 10.1016/j.ijcard.2012.06.020. [PubMed: 22726399].
  • 24. Tarantino G, Scalera A, Finelli C. Liver-spleen axis: intersection between immunity, infections and metabolism. World J Gastroenterol. 2013;19(23):3534-42. doi: 10.3748/wjg.v19.i23.3534. [PubMed: 23801854].
  • 25. Robinette CD, Fraumeni J. Splenectomy and subsequent mortality in veterans of the 1939-45 war. Lancet. 1977;310(8029):127-9.
  • 26. Quijada Z, Paoli M, Zerpa Y, Camacho N, Cichetti R, Villarroel V, et al. The triglyceride/HDL-cholesterol ratio as a marker of cardiovascular risk in obese children; association with traditional and emergent risk factors. Pediatr Diabetes. 2008;9(5):464-71. doi: 10.1111/j.1399-5448.2008.00406.x. [PubMed: 18507788].
  • 27. Aghel N, Rashidi I, Mombeini A. Hepatoprotective activity of Capparis spinosa root bark against CCl4 induced hepatic damage in mice. Iran J Pharmaceutic Res. 2010:285-90.
  • 28. El Azhary K, Tahiri Jouti N, El Khachibi M, Moutia M, Tabyaoui I, El Hou A, et al. Anti-inflammatory potential of Capparis spinosa L. in vivo in mice through inhibition of cell infiltration and cytokine gene expression. BMC Complement Altern Med. 2017;17(1):81. doi: 10.1186/s12906-017-1569-7. [PubMed: 28143472].
  • 29. Anila L, Vijayalakshmi N. Flavonoids from Emblica officinalis and Mangifera indica—effectiveness for dyslipidemia. J Ethnopharmacol. 2002;79(1):81-7.
  • 30. Germano MP, De Pasquale R, D'Angelo V, Catania S, Silvari V, Costa C. Evaluation of extracts and isolated fraction from Capparis spinosa L. buds as an antioxidant source. J Agric Food Chem. 2002;50(5):1168-71. [PubMed: 11853498].
  • 31. Eddouks M, Lemhadri A, Michel JB. Hypolipidemic activity of aqueous extract of Capparis spinosa L. in normal and diabetic rats. J Ethnopharmacol. 2005;98(3):345-50. doi: 10.1016/j.jep.2005.01.053. [PubMed: 15814271].
  • 32. Eddouks M, Lemhadri A, Hebi M, El Hidani A, Zeggwagh NA, El Bouhali B, et al. Capparis spinosa L. aqueous extract evokes antidiabetic effect in streptozotocin-induced diabetic mice. Avicenna J Phytomed. 2017;7(2):191-8. [PubMed: 28348974].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments